X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs PANACEA BIOTECH - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE PANACEA BIOTECH CADILA HEALTHCARE/
PANACEA BIOTECH
 
P/E (TTM) x 19.1 -16.9 - View Chart
P/BV x 4.3 2.0 216.5% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 CADILA HEALTHCARE   PANACEA BIOTECH
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
PANACEA BIOTECH
Mar-14
CADILA HEALTHCARE/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs558149 375.3%   
Low Rs36282 439.2%   
Sales per share (Unadj.) Rs116.384.1 138.2%  
Earnings per share (Unadj.) Rs17.9-18.3 -97.6%  
Cash flow per share (Unadj.) Rs23.1-6.7 -345.3%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.483.7 102.0%  
Shares outstanding (eoy) m1,023.7461.25 1,671.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.01.4 288.0%   
Avg P/E ratio x25.7-6.3 -407.8%  
P/CF ratio (eoy) x19.9-17.2 -115.3%  
Price / Book Value ratio x5.41.4 390.1%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,6647,074 6,653.1%   
No. of employees `00011.82.8 429.8%   
Total wages/salary Rs m18,5451,449 1,279.7%   
Avg. sales/employee Rs Th10,072.71,874.1 537.5%   
Avg. wages/employee Rs Th1,569.1527.0 297.7%   
Avg. net profit/employee Rs Th1,547.7-407.7 -379.6%   
INCOME DATA
Net Sales Rs m119,0495,154 2,310.0%  
Other income Rs m1,132100 1,134.3%   
Total revenues Rs m120,1815,254 2,287.6%   
Gross profit Rs m28,475-766 -3,715.9%  
Depreciation Rs m5,388711 757.8%   
Interest Rs m9111,503 60.6%   
Profit before tax Rs m23,308-2,881 -809.2%   
Minority Interest Rs m62811 5,814.8%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m5,64417 33,595.2%   
Profit after tax Rs m18,292-1,121 -1,631.3%  
Gross profit margin %23.9-14.9 -160.9%  
Effective tax rate %24.2-0.6 -4,151.8%   
Net profit margin %15.4-21.8 -70.6%  
BALANCE SHEET DATA
Current assets Rs m82,0053,810 2,152.2%   
Current liabilities Rs m60,7208,365 725.9%   
Net working cap to sales %17.9-88.4 -20.2%  
Current ratio x1.40.5 296.5%  
Inventory Days Days73156 47.0%  
Debtors Days Days9867 146.2%  
Net fixed assets Rs m83,70314,480 578.1%   
Share capital Rs m1,02461 1,670.5%   
"Free" reserves Rs m86,421903 9,569.4%   
Net worth Rs m87,4455,127 1,705.5%   
Long term debt Rs m25,5515,832 438.1%   
Total assets Rs m180,65319,433 929.6%  
Interest coverage x26.6-0.9 -2,900.7%   
Debt to equity ratio x0.31.1 25.7%  
Sales to assets ratio x0.70.3 248.5%   
Return on assets %10.62.0 541.2%  
Return on equity %20.9-21.9 -95.6%  
Return on capital %22.03.6 604.7%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m42,6831,539 2,773.1%   
Fx outflow Rs m11,242942 1,193.4%   
Net fx Rs m31,441597 5,264.7%   
CASH FLOW
From Operations Rs m9,193599 1,534.2%  
From Investments Rs m-9,737-438 2,223.6%  
From Financial Activity Rs m515-303 -170.2%  
Net Cashflow Rs m-29-141 20.5%  

Share Holding

Indian Promoters % 74.8 74.5 100.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.6 1,383.3%  
FIIs % 5.9 1.3 453.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 23.6 46.6%  
Shareholders   44,069 10,259 429.6%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 150 Points Up; Oil & Gas Stocks Lead(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares show losses. The Nikkei 225 is up 0.3% while the Hang Seng is down 0.1%.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Nov 14, 2018 12:11 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS